No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and...Read more
After more than five years of follow-up, CABOMETYX in combination with Opdivo continued to show survival benefit compared with sunitinib Long-term efficacy seen across subgroups, including site of metastases ALAMEDA, Calif. / Feb 15, 2025 / Business Wire / Exelixis, Inc....Read more
IMFINZI reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone WILMINGTON, Del. / Feb 14, 2025 / Business Wire / Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI®...Read more
First Major Technological Breakthrough in Hyaluronic Acid Dermal Fillers in a Decade; U.S. Launch Planned in Q2 2025 Launch Establishes Evolus as a Multi-Product Performance Beauty Company and Expands Addressable Market by 78% NEWPORT BEACH, Calif. / Feb 13, 2025 / Business Wire / Evolus, Inc....Read more
Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 HOUSTON, Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company...Read more
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution New tablet formulation may provide greater freedom...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORECompany | Change | Last Trade |
---|---|---|
Abbott | 15.62 13.58 | $130.61 |
West Pharmaceutical | 15.49 7.78 | $214.60 |
AbbVie | 13.67 7.63 | $192.87 |
Finch Therapeutics | 13.20 733.33 | $15.00 |
Glaukos | 6.82 4.66 | $153.20 |
CRISPR Therapeutics | 6.36 14.62 | $49.85 |
Ligand Pharmaceuticals | 6.07 5.33 | $120.00 |
Tempus AI | 5.75 6.87 | $89.50 |
DexCom | 4.98 5.92 | $89.07 |
Cytokinetics | 4.54 10.91 | $46.16 |
Intuitive Surgical | 4.16 0.70 | $595.55 |
Praxis Precision Medicines | 4.11 4.74 | $90.77 |
Beam Therapeutics | 3.79 13.25 | $32.40 |
ICON | 3.57 1.95 | $186.21 |
BridgeBio Pharma | 3.34 10.58 | $34.90 |
Absci | 3.06 110.43 | $5.83 |
Aligos Therapeutics | 2.99 14.23 | $24.00 |
Danaher | 2.71 1.33 | $206.30 |
Company | Volume | Last Trade |
---|---|---|
CNS Pharmaceuticals | 480,732,013 | $0.15 |
OS Therapies | 244,230,691 | $2.16 |
Moleculin Biotech | 134,843,523 | $2.18 |
Virpax Pharmaceuticals | 118,886,367 | $0.31 |
Petros Pharmaceuticals | 106,063,818 | $0.30 |
Aditxt | 85,552,088 | $0.07 |
Recursion | 81,151,781 | $10.54 |
PacBio | 45,559,729 | $1.84 |
Allogene Therapeutics | 42,238,673 | $2.04 |
Ocean Biomedical | 41,004,441 | $0.13 |
KindlyMD | 31,070,741 | $2.94 |
Pfizer | 25,448,679 | $25.53 |
Tempus AI | 24,864,184 | $89.50 |
Moderna | 24,662,791 | $32.99 |
Merck | 23,880,845 | $83.01 |
Geron | 22,737,482 | $2.56 |
AEON Biopharma | 21,871,017 | $0.13 |
Senseonics | 20,968,077 | $1.24 |
Teladoc Health | 20,183,792 | $14.33 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORERecursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE